Abstract:Aim: To study the hypoglycemic effect of rhFGF21 in vitro and in vivo by using liver cells, muscle cells, preadipocytes and ob/ob mice. Methods: GOD-POD kits were used for determination of cellular glucose uptake in normal human liver cell line (HL7702) , rat muscle cell line(L-6) , and mouse preadipocytes (3T3-L1) ; rhFGF-21 was subcutaneously and continuously injected, at the dose of 0.6 μg·g -1 per day, for 7 days, and the levels of fasting blood glucose on day 0, 3 and 7 after administration were recorded and compared to those of the saline-treated control; rhFGF-21 was subcutaneously and continuously injected, at the dose of 0.6 μg·g -1 per day, for 9 days. Oral glucose tolerance test was done 1 h after the last administration. Briefly, glucose solution was administered intragastrically at the dose of 2 mg·g -1, and the concentration of blood glucose was detected 30 min, 60 min, 120 min after glucose administration; rhFGF-21 was subcutaneously and continuously injected, at the dose of 2.5 μg¶g -1 per day, for 7 days, and postprandial blood glucose concentrations were detected on day 0,3, and 7 after the administration. Results: rhFGF21 at the concentration of 3. 9 mg·L -1 ∼ 100 mg ·L -1 significantly promoted glucose absorption in HL7702 cells in a dose-dependent manner (P < 0.01) ; rhFGF21 at the dose of 0.3 mg·L -1 ∼ 250 mg·L -1 significantly increased glucose consumption in L6 muscle cells(P <0.05) ; rhFGF21 at the dose of 12.6 mg ·L -1 ∼100 mg·L -1 significantly promoted the glucose absorption in differentiated 3T3-L1 cells in a dose-dependent manner (P < 0.05) ; in vivo blood glucose experiment showed that rhFGF-21 treatment greatly reduced blood glucose concentration and improved glucose tolerance in ob/ob mice. Conclusions: rhFGF21 treatment increases glucose absorption in liver cells, muscle cells and adipose cells; rhFGF-21 treatment also reduces fasting and postprandial blood glucose concentration in ob/ob mice, exhibiting its function of improving the amount of glucose tolerance.

Optimization and Characterization of a Novel FGF21 Mutant

Enhancement of FGF21 Expression by Site-Directed Mutagenesis

[Expression and Pharmacological Evaluation of Fusion Protein FGF21-L-Fc].

Stability and Glucose Regulation of FGF21 after Modified with Arginines*

[Cloning, Expression and Glucose Regulation Activity of Human FGF-21].

Cloning, expression and glucose regulation activity of human FGF-21 HOU Yu-Ting, LI Jin-Nan, REN Gui-Ping, LIU Ming-Yao, SUN Guo-Peng, WANG Wen-Fei, LI De-Shan

Utilization of SUMO Expression Vector to Efficiently Express Mouse FGF-21 and Studying of Its Bioactivity

[Efficient Expression of Soluble Human FGF-21 and Its Glucose Regulation Activity].

[Improvement of Yield and Purity of Human Fibroblast Growth Factor-21].

Large-Scale Expression, Purification, and Glucose Uptake Activity of Recombinant Human Fgf21 in Escherichia Coli

Enhancement of the pharmacological efficacy of FGF-21 by genetic modification and PEGylation

Design and characterization of a FGF1‐FGF21 chimeric protein with increased stability and enhanced antidiabetic activities

The studies on hypoglycemic effect of rhFGF21 both in vitro and in vivo

Cellular Mechanisms by Which Fgf21 Improves Insulin Sensitivity in Male Mice

FGF21 Normalizes Plasma Glucose in Mouse Models of Type 1 Diabetes and Insulin Receptor Dysfunction

Human Fibroblast Growth Factor-21 Regulates Glucose Uptake in 3T3-L1 Adipocytes

Paracrine-endocrine FGF Chimeras As Potent Therapeutics for Metabolic Diseases.

A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis

Double promoter and tandem gene strategy for efficiently expressing recombinant FGF21

Fibroblast Growth Factor 21 Improves Glucose Homeostasis Partially Via Down-Regulation of Na+-d-glucose Cotransporter SGLT1 in the Small Intestine.

Pilot-scale Production and Characterization of PEGylated Human FGF-21 Analog.